Form 8-K

8-K — Medtronic plc

Accession: 0001628280-26-059697

Filed: 2026-09-01

Period: 2026-09-01

CIK: 0001613103

SIC: 3845 (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — mdt-20260901.htm (Primary)

EX-99.1 (exhibit991-fy27q1earningsr.htm)

GRAPHIC — IMAGE 0 (image_0a.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: mdt-20260901.htm · Sequence: 1

mdt-20260901

0001613103H91 4K49false00016131032026-09-012026-09-010001613103mdt:A1.125SeniorNotesDue2027Member2026-09-012026-09-010001613103mdt:A0.375SeniorNotesDue2028Member2026-09-012026-09-010001613103mdt:A3.000SeniorNotesDue2028Member2026-09-012026-09-010001613103mdt:A3.650SeniorNotesDue2029Member2026-09-012026-09-010001613103mdt:A2.950SeniorNotesDue2030Member2026-09-012026-09-010001613103mdt:A1.625SeniorNotesDue2031Member2026-09-012026-09-010001613103mdt:A1.000SeniorNotesDue2031Member2026-09-012026-09-010001613103mdt:A3.125SeniorNotesDue2031Member2026-09-012026-09-010001613103mdt:A0.750SeniorNotesDue2032Member2026-09-012026-09-010001613103mdt:A3.375SeniorNotesDue2034Member2026-09-012026-09-010001613103mdt:A3.875SeniorNotesDue2036Member2026-09-012026-09-010001613103mdt:A2.250SeniorNotesDue2039Member2026-09-012026-09-010001613103mdt:A1.500SeniorNotesDue2039Member2026-09-012026-09-010001613103mdt:A1.375SeniorNotesDue2040Member2026-09-012026-09-010001613103mdt:A4.150SeniorNotesDue2043Member2026-09-012026-09-010001613103mdt:A4.200SeniorNotesDue2045Member2026-09-012026-09-010001613103mdt:A1.750SeniorNotesDue2049Member2026-09-012026-09-010001613103mdt:A1.625SeniorNotesDue2050Member2026-09-012026-09-010001613103mdt:A4.150SeniorNotesDue2053Member2026-09-012026-09-01

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________

FORM 8-K

_____________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 1, 2026

_____________________________

Medtronic plc

(Exact name of Registrant as Specified in its Charter)

_____________________________

Ireland 1-36820 98-1183488

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

Building Two

Parkmore Business Park West

Galway, Ireland

(Address of principal executive offices) (Zip Code)

+353 1 438-1700

(Registrant’s telephone number, including area code)

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol Name of each exchange on which registered

Ordinary shares, par value $0.0001 per share MDT New York Stock Exchange

1.125% Senior Notes due 2027 MDT/27 New York Stock Exchange

0.375% Senior Notes due 2028 MDT/28 New York Stock Exchange

3.000% Senior Notes due 2028 MDT/28A New York Stock Exchange

3.650% Senior Notes due 2029 MDT/29 New York Stock Exchange

2.950% Senior Notes due 2030 MDT/30 New York Stock Exchange

1.625% Senior Notes due 2031 MDT/31 New York Stock Exchange

1.000% Senior Notes due 2031 MDT/31A New York Stock Exchange

3.125% Senior Notes due 2031 MDT/31B New York Stock Exchange

0.750% Senior Notes due 2032 MDT/32 New York Stock Exchange

3.375% Senior Notes due 2034 MDT/34 New York Stock Exchange

3.875% Senior Notes due 2036 MDT/36 New York Stock Exchange

2.250% Senior Notes due 2039 MDT/39A New York Stock Exchange

1.500% Senior Notes due 2039 MDT/39B New York Stock Exchange

1.375% Senior Notes due 2040 MDT/40A New York Stock Exchange

4.150% Senior Notes due 2043 MDT/43A New York Stock Exchange

4.200% Senior Notes due 2045 MDT/45 New York Stock Exchange

1.750% Senior Notes due 2049 MDT/49 New York Stock Exchange

1.625% Senior Notes due 2050 MDT/50 New York Stock Exchange

4.150% Senior Notes due 2053 MDT/53 New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition

On September 1, 2026, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its first quarter fiscal year 2027 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01. Exhibits.

(d) List of Exhibits

Exhibit Number Description

99.1

Press release of Medtronic plc, dated September 1, 2026

104

Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medtronic plc

By /s/ Thierry Piéton

Date: September 1, 2026

Thierry Piéton

Executive Vice President and Chief Financial Officer (Principal Financial Officer)

EXHIBIT INDEX

Exhibit Number Description

99.1

Press release of Medtronic plc, dated September 1, 2026

104

Cover Page Interactive Data File (embedded with the Inline XBRL document).

EX-99.1

Filename: exhibit991-fy27q1earningsr.htm · Sequence: 2

Document

Exhibit 99.1

NEWS RELEASE

FOR IMMEDIATE RELEASE

Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance

Strength across the company’s largest franchises, new growth platforms, and recent portfolio investments support the long-term growth trajectory

GALWAY, Ireland – September 1, 2026 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2027 (FY27), which ended July 31, 2026.

Key Highlights

•Revenue of $9.8 billion, increased 13.7% as reported and 13.7% organic, roughly 200 basis points above guidance midpoint

•GAAP diluted EPS of $1.14; non-GAAP diluted EPS of $1.45, ahead of guidance

•Raising FY27 organic revenue growth guidance 50 basis points to 7.25% to 7.75%, and FY27 diluted non-GAAP EPS guidance to the new range of $5.94 to $6.00

•Cardiovascular grew 18.9%, led by 15% growth in Cardiac Rhythm Management and 88% growth in Cardiac Ablation Solutions

•Announced expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias

•Announces strategic investment in Pi-Cardia, a pioneer in leaflet modification technology

•Neuroscience grew 9.3%, driven by 13% growth in Cranial and Spinal Technologies, including low-20s growth in enabling technology; Altaviva meaningfully contributed to 15% growth in Pelvic Health

•Medical Surgical reported strong performance, up 10.2%, led by 9% growth in Surgical and 14% growth in Acute Care & Monitoring

•Announces strategic partnership with Cornerstone Robotics to further expand global access to robotic-assisted surgery

•Announced FDA clearance for Touch Surgery™ Aide next generation computing platform

•Completed acquisitions of Scientia Vascular and SPR Therapeutics, Inc.

“We are off to a strong start in fiscal 2027. What gives us confidence is not simply the strength of the quarter, but importantly, the breadth of performance across our businesses and the increasing contributions from newer growth platforms,” said Geoff Martha, Medtronic chairman and chief executive officer. “Our execution, alongside our innovation engine, positions us to serve more patients and deliver durable growth. The strength of our portfolio and pipeline gives us confidence in the opportunities ahead.”

Financial Results

Medtronic reported Q1 worldwide revenue of $9.756 billion, an increase of 13.7% as reported and 13.7% on an organic basis. The Q1 FY27 organic revenue growth comparison excludes:

•Other revenue of $29 million in the current year versus $72 million in the prior year

•Revenue from the Dutch Obesity Clinic (NOK) divestiture with no revenue in the current year and $17 million in the prior year

•Scientia revenue of $14 million (closed June 12) and SPR Therapeutics revenue of $5 million in the current year (closed July 16)

•Foreign exchange benefit of $57 million on the remaining net sales

Results were impacted by the extra fiscal week, which occurred in Medtronic’s first quarter of FY27. The company estimates the impact of the extra week benefited Q1 organic growth by approximately $570 million.

Q1 revenue included:

•Cardiovascular Portfolio revenue of $3.927 billion increased 19.5% as reported and 18.9% organic, with high-20s increase in Electrophysiology Therapies, high-single digit increase in Interventional Cardiology Therapies, high-single digit increase in CardioVascular Surgery, and low-double digit increase in Peripheral Vascular Health, all on an organic basis

•Neuroscience Portfolio revenue of $2.678 billion increased 10.3% reported and 9.3% organic, with low-double digit increase in Cranial & Spinal Technologies, high-single digit increase in Specialty Therapies, and low-single digit increase in Neuromodulation, all on an organic basis

•Medical Surgical Portfolio revenue of $2.279 billion increased 10.0% as reported and 10.2% organic, with high-single digit increase in Surgical & Endoscopy, and mid-teens increase in Acute Care & Monitoring, all on an organic basis

•Diabetes business revenue of $843 million increased 16.9% as reported and 14.9% organic1

Q1 GAAP operating profit and operating margin were $1.764 billion and 18.1%, respectively, an increase of 22.1% and 120 basis points, respectively. As detailed in the financial schedules included at the end of the release, Q1 non-GAAP operating profit and operating margin were $2.316 billion and 23.7%, respectively, an increase of 14.9% and 10 basis points, respectively.

Q1 GAAP net income and diluted earnings per share (EPS) were $1.470 billion and $1.14, respectively, representing increases of 41.4% and 40.7%, respectively. As detailed in the financial schedules included at the end of this release, Q1 non-GAAP net income and non-GAAP diluted EPS were $1.860 billion and $1.45 respectively, representing increases of 14.4% and 15.1%, respectively.

Guidance

The company today raised its FY27 organic revenue growth and EPS guidance. The company raised its FY27 organic revenue growth guidance to 7.25% to 7.75%, an increase from the prior guidance of 6.75% to 7.25%. The company also raised its FY27 diluted non-GAAP EPS guidance to the new range of $5.94 to $6.00 versus the prior $5.90 to $6.00. This guidance includes an estimated neutral to 1% accretive impact from foreign currency exchange based on recent rates.

“We continue to make targeted investments in innovation, portfolio development, and commercial execution that will support sustainable long-term value creation,” said Thierry Piéton, Medtronic chief financial officer. “The combination of strong operating performance and disciplined financial management drove revenue and adjusted EPS ahead of expectations, enabling us to raise our fiscal 2027 guidance.”

Video Webcast Information

Medtronic will host a video webcast today, September 1, at 7:45 a.m. EST (6:45 a.m. CST) to provide information about its business for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Quarterly Earnings icon at investorrelations.medtronic.com, and this earnings release will be archived at news.medtronic.com. Within 24 hours of the webcast, a replay of the webcast and transcript of the company’s prepared remarks will be available by clicking on the Past Events and Presentations link under the News & Events drop-down at investorrelations.medtronic.com.

Financial Schedules

The first quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Quarterly Earnings link at investorrelations.medtronic.com.

About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow on LinkedIn.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, material acquisition and divestiture transactions, general economic conditions, and other risks and uncertainties described in the company’s periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “looking ahead,” “may,” “plan,” “possible,” “potential,” “project,” “should,” “going to,” “will,” and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any

of the information contained in this press release, including to reflect future events or circumstances.

NON-GAAP FINANCIAL MEASURES

This press release contains guidance and financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Certain information in this press release also includes calculations or figures that have been prepared internally and have not been reviewed or audited by our independent registered public accounting firm. Use of different methods for preparing, calculating or presenting information may lead to differences and such differences may be material.

Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company’s underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management’s review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company’s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.

Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, revenue in the current and prior year reported as "Other”, as well as significant acquisitions, divestitures, or other significant discrete items. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is

inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.

FINANCIAL COMPARISONS

References to quarterly or annual figures increasing, decreasing, or remaining flat are in comparison to fiscal year 2026, and references to sequential changes are in comparison to the prior fiscal quarter. Unless stated otherwise, quarterly and annual rates and ranges are given on an organic basis. References to organic revenue growth exclude the impact of foreign currency, first quarter revenue in the current and prior year reported as "Other”, as well as significant acquisitions, divestitures, or other significant discrete items.

TRANSACTION DETAILS

The separation of our Diabetes business has involved and is expected to be completed through a series of capital markets transactions, which may include a spin-off, split-off, offering, or combination thereof. While a split-off is the company's current preferred separation structure, a final decision has not been reached at this time.

-end-

Contacts:

Justin Paquette

Public Relations

+1-612-271-7935

Ingrid Goldberg

Investor Relations

+1-763-505-2696

______________________

1The Diabetes results presented here may not correspond to the same financial statement information presented by MiniMed Group, Inc. (MiniMed) due to MiniMed’s financials being prepared on a carve out basis through the date of the company’s initial public offering (IPO) and on a standalone basis post IPO.

FINANCIAL SCHEDULES Page

Worldwide Revenue

U.S. Revenue

International Revenue

Condensed Consolidated Statements of Income

GAAP to Non-GAAP Reconciliations

Condensed Consolidated Statements of Cash Flows

MEDTRONIC PLC

WORLDWIDE REVENUE(1)

(Unaudited)

FIRST QUARTER(2)

REPORTED ORGANIC

(in millions) FY27 FY26 Growth

Currency Impact(7)

FY27(8)

FY26(8)

Growth

Cardiovascular(3)

$ 3,927 $ 3,285 19.5 % $ 21 $ 3,906 $ 3,285 18.9 %

Electrophysiology Therapies 2,218 1,712 29.5 8 2,210 1,712 29.1

Interventional Cardiology Therapies 894 834 7.2 6 889 834 6.5

CardioVascular Surgery 477 436 9.3 5 472 436 8.1

Peripheral Vascular Health 338 302 11.6 2 336 302 11.0

Neuroscience(3)

2,678 2,427 10.3 6 2,653 2,427 9.3

Cranial & Spinal Technologies 1,365 1,211 12.8 (2) 1,367 1,211 12.9

Specialty Therapies 774 702 10.2 6 754 702 7.4

Neuromodulation(3)

539 514 4.7 2 531 514 3.3

Medical Surgical(3)

2,279 2,073 10.0 15 2,265 2,056 10.2

Surgical & Endoscopy(3)

1,740 1,601 8.7 14 1,726 1,584 9.0

Acute Care & Monitoring 539 471 14.4 1 538 471 14.2

Total Reportable Segments 8,884 7,785 14.1 43 8,823 7,768 13.6

Diabetes(4)

843 721 16.9 14 829 721 14.9

Other(5)

29 72

NM(6)

— — — —

TOTAL $ 9,756 $ 8,578 13.7 % $ 57 $ 9,652 $ 8,489 13.7 %

See description of non-GAAP financial measures contained in the press release dated September 1, 2026.

(1)The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

(2)Fiscal year 2027 is a 53-week fiscal year, with the extra week occurring in the first fiscal month of the first quarter and included in reported first quarter results. While it is difficult to calculate the impact of the extra week, the Company estimates the extra week benefited first quarter organic growth by approximately $570 million.

(3)In fiscal year 2027, the Cardiovascular Portfolio divisions transitioned from Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular to Electrophysiology Therapies, Interventional Cardiology Therapies, CardioVascular Surgery, and Peripheral Vascular Health. Additionally, there was a product line that moved from the Medical Surgical Portfolio in the Surgical & Endoscopy division to the Neuroscience Portfolio in the Neuromodulation division. Prior year net sales has been recast to conform to the current year presentation.

(4)The Diabetes results presented here may not correspond to the same financial statement information presented by MiniMed Group, Inc. (MiniMed). The Diabetes Business as reported by Medtronic is prepared on a different basis than standalone Medtronic due to MiniMed’s financials being prepared on a carve out basis through the date of the company’s initial public offering (IPO) and on a standalone basis post IPO.

(5)Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, and adjustments to the Company's Italian payback accruals resulting from the June 30, 2025 Legislative Decree published by the Italian Government for years 2015 to 2018.

(6)Not meaningful (NM).

(7)The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.

(8)The three months ended July 31, 2026 excludes $104 million of revenue adjustments, including $29 million of inorganic revenue for the transition activity noted in (5), $14 million of inorganic revenue related to the Scientia Vascular (Scientia) acquisition in the Specialty Therapies division, $5 million of inorganic revenue related to the SPR Therapeutics, Inc. (SPR) acquisition in the Neuromodulation division, and $57 million of favorable currency impact on the remaining net sales. The three months ended July 25, 2025 excludes $89 million of revenue adjustments, including $33 million of inorganic revenue for the transition activity noted in (5), $39 million reduction in the Italian payback accruals due to changes in estimates further described in note (5), and $17 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division.

MEDTRONIC PLC

U.S. REVENUE(1)(2)

(Unaudited)

FIRST QUARTER(3)

REPORTED ORGANIC

(in millions) FY27 FY26 Growth

FY27(7)

FY26(7)

Growth

Cardiovascular(4)

$ 1,853 $ 1,479 25.3 % $ 1,853 $ 1,479 25.3 %

Electrophysiology Therapies 1,177 834 41.2 1,177 834 41.2

Interventional Cardiology Therapies 294 296 (0.8) 294 296 (0.8)

CardioVascular Surgery 186 170 9.6 186 170 9.6

Peripheral Vascular Health 196 180 9.2 196 180 9.2

Neuroscience 1,813 1,624 11.7 1,795 1,624 10.5

Cranial & Spinal Technologies 1,016 890 14.1 1,016 890 14.1

Specialty Therapies 447 393 13.8 434 393 10.4

Neuromodulation 350 341 2.6 345 341 1.2

Medical Surgical 982 884 11.1 982 884 11.1

Surgical & Endoscopy 671 622 7.9 671 622 7.9

Acute Care & Monitoring 311 263 18.5 311 263 18.5

Total Reportable Segments 4,649 3,988 16.6 4,630 3,988 16.1

Diabetes(5)

240 217 10.6 240 217 10.6

Other(6)

17 20 (12.1) — — —

TOTAL $ 4,906 $ 4,224 16.1 % $ 4,870 $ 4,205 15.8 %

See description of non-GAAP financial measures contained in the press release dated September 1, 2026.

(1)U.S. includes the United States and U.S. territories.

(2)The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

(3)Fiscal year 2027 is a 53-week fiscal year, with the extra week occurring in the first fiscal month of the first quarter and included in reported first quarter results.

(4)In fiscal year 2027, the Cardiovascular Portfolio divisions transitioned from Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular to Electrophysiology Therapies, Interventional Cardiology Therapies, CardioVascular Surgery, and Peripheral Vascular Health. Prior year net sales has been recast to conform to the current year presentation.

(5)The Diabetes results presented here may not correspond to the same financial statement information presented by MiniMed Group, Inc. (MiniMed). The Diabetes Business as reported by Medtronic is prepared on a different basis than standalone Medtronic due to MiniMed’s financials being prepared on a carve out basis through the date of the company’s initial public offering (IPO) and on a standalone basis post IPO.

(6)Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested.

(7)The three months ended July 31, 2026 excludes $36 million of revenue adjustments, including $17 million of inorganic revenue for the transition activity noted in (6), $14 million of inorganic revenue related to the Scientia acquisition in the Specialty Therapies division, and $5 million of inorganic revenue related to the SPR acquisition in the Neuromodulation division. The three months ended July 25, 2025 excludes $20 million of revenue adjustments, including $20 million of inorganic revenue for the transition activity noted in (6).

MEDTRONIC PLC

INTERNATIONAL REVENUE(1)

(Unaudited)

FIRST QUARTER(2)

REPORTED ORGANIC

(in millions) FY27 FY26 Growth

Currency Impact(7)

FY27(8)

FY26(8)

Growth

Cardiovascular(3)

$ 2,074 $ 1,806 14.8 % $ 21 $ 2,053 $ 1,806 13.7 %

Electrophysiology Therapies 1,041 878 18.5 8 1,033 878 17.6

Interventional Cardiology Therapies 601 538 11.6 6 595 538 10.5

CardioVascular Surgery 291 266 9.2 5 285 266 7.2

Peripheral Vascular Health 142 123 15.3 2 140 123 13.7

Neuroscience(3)

864 803 7.6 6 858 803 6.8

Cranial & Spinal Technologies 349 320 9.0 (2) 351 320 9.5

Specialty Therapies 326 309 5.6 6 321 309 3.7

Neuromodulation(3)

189 174 8.9 2 186 174 7.4

Medical Surgical(3)

1,297 1,188 9.2 15 1,282 1,171 9.5

Surgical & Endoscopy(3)

1,070 980 9.2 14 1,055 963 9.6

Acute Care & Monitoring 228 209 9.2 1 227 209 8.8

Total Reportable Segments 4,236 3,797 11.5 43 4,193 3,780 10.9

Diabetes(4)

603 504 19.6 14 589 504 16.8

Other(5)

12 53

NM(6)

— — — —

TOTAL $ 4,850 $ 4,354 11.4 % $ 57 $ 4,782 $ 4,284 11.6 %

See description of non-GAAP financial measures contained in the press release dated September 1, 2026.

(2)Fiscal year 2027 is a 53-week fiscal year, with the extra week occurring in the first fiscal month of the first quarter and included in reported first quarter results.

(6)Not meaningful (NM).

(7)The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.

(8)The three months ended July 31, 2026 excludes $68 million of revenue adjustments, including $12 million of inorganic revenue for the transition activity noted in (5) and $57 million of favorable currency impact on the remaining net sales. The three months ended July 25, 2025 excludes $70 million of revenue adjustments, including $14 million of inorganic revenue related to the transition activity noted in (5), $39 million reduction in the Italian payback accruals due to changes in estimates further described in note (5), and $17 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division.

MEDTRONIC PLC

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

Three months ended

(in millions, except per share data) July 31, 2026 July 25, 2025

Net sales $ 9,756 $ 8,578

Costs and expenses:

Cost of products sold, excluding amortization of intangible assets 3,416 3,001

Research and development expense 771 726

Selling, general, and administrative expense 3,198 2,806

Amortization of intangible assets 412 459

Restructuring charges, net 72 45

Certain litigation charges, net — 27

Other operating expense (income), net 123 70

Operating profit 1,764 1,445

Other non-operating expense (income), net (190) (33)

Interest expense, net 186 176

Income before income taxes 1,769 1,302

Income tax provision 289 255

Net income 1,479 1,047

Net income attributable to noncontrolling interests (9) (7)

Net income attributable to Medtronic $ 1,470 $ 1,040

Basic earnings per share $ 1.15 $ 0.81

Diluted earnings per share $ 1.14 $ 0.81

Basic weighted average shares outstanding 1,279.8 1,281.6

Diluted weighted average shares outstanding 1,285.1 1,287.1

The data in the schedule above has been intentionally rounded to the nearest million.

MEDTRONIC PLC

GAAP TO NON-GAAP RECONCILIATIONS(1)

(Unaudited)

Three months ended July 31, 2026

(in millions, except per share data) Net Sales Cost of Products Sold Gross Margin Percent Operating Profit Operating Profit Percent Income Before Income Taxes Net Income attributable to Medtronic Diluted EPS Effective Tax Rate

GAAP $ 9,756 $ 3,416 65.0 % $ 1,764 18.1 % $ 1,769 $ 1,470 $ 1.14 16.4 %

Non-GAAP Adjustments:

Amortization of intangible assets — — — 412 4.2 412 337 0.26 18.2

Restructuring and associated costs(2)

— (8) 0.1 89 0.9 89 70 0.05 21.2

Acquisition and divestiture-related items(3)

— (11) 0.1 50 0.5 50 41 0.03 18.2

(Gain)/loss on minority investments(4)

— — — — — (64) (64) (0.05) (0.1)

Certain tax adjustments, net(5)

— — — — — — 5 — —

Non-GAAP $ 9,756 $ 3,396 65.2 % $ 2,316 23.7 % $ 2,257 $ 1,860 $ 1.45 17.2 %

Currency impact (57) (21) — (27) (0.1) (0.02)

Currency Adjusted $ 9,699 $ 3,375 65.2 % $ 2,290 23.6 % $ 1.43

Three months ended July 25, 2025

GAAP $ 8,578 $ 3,001 65.0 % $ 1,445 16.8 % $ 1,302 $ 1,040 $ 0.81 19.6 %

Non-GAAP Adjustments:

Amortization of intangible assets(6)

— — — 459 5.5 459 374 0.29 18.5

Restructuring and associated costs(2)

— (16) 0.1 67 0.8 67 51 0.04 22.4

Acquisition and divestiture-related items(3)

— (7) — 58 0.7 58 48 0.04 17.2

Certain litigation charges, net — — — 27 0.3 27 21 0.02 22.2

(Gain)/loss on minority investments(4)

— — — — — 113 107 0.08 6.2

Other(7)

(39) — (0.2) (39) (0.5) (39) (30) (0.02) 20.5

Certain tax adjustments, net(5)

— — — — — — 16 0.01 —

Non-GAAP $ 8,539 $ 2,979 65.1 % $ 2,016 23.6 % $ 1,987 $ 1,626 $ 1.26 17.8 %

See description of non-GAAP financial measures contained in the press release dated September 1, 2026.

(1)The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.

(2)The charges primarily relate to employee termination benefits, facility related and contract termination costs, and asset write offs.

(3)The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. Exit of business-related charges primarily relate to the impending separation of the Diabetes Business and costs associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System.

(4)We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.

(5)The net charges for the three months ended July 31, 2026 and July 25, 2025, primarily relate to amortization of previously established deferred tax assets arising from previous intercompany intellectual property transactions. The net charges for the three months ended July 31, 2026, were partially offset by the release of reserves for uncertain tax positions on prior period intercompany transactions.

(6)The Company recognized $45 million of accelerated amortization on certain intangible assets within the Cardiovascular Portfolio.

(7)Reflects adjustments to the Company's Italian payback accruals resulting from the June 30, 2025 Legislative Decree published by the Italian government for years 2015 to 2018.

MEDTRONIC PLC

GAAP TO NON-GAAP RECONCILIATIONS(1)

(Unaudited)

Three months ended July 31, 2026

(in millions) Net Sales SG&A Expense SG&A Expense as a % of Net Sales R&D Expense R&D Expense as a % of Net Sales Other Operating Expense (Income), net Other Operating Exp./(Inc.), net as a % of Net Sales Other Non-Operating Expense (Income), net

GAAP $ 9,756 $ 3,198 32.8 % $ 771 7.9 % $ 123 1.3 % $ (190)

Non-GAAP Adjustments:

Restructuring and associated costs(2)

— (10) (0.1) — — — — —

Acquisition and divestiture-related items(3)

— (26) (0.3) — — (13) (0.1) —

(Gain)/loss on minority investments(4)

— — — — — — — 64

Non-GAAP $ 9,756 $ 3,162 32.4 % $ 771 7.9 % $ 110 1.1 % $ (127)

See description of non-GAAP financial measures contained in the press release dated September 1, 2026.

(1)The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.

(2)The charges primarily relate to employee termination benefits, facility related and contract termination costs, and asset write offs.

MEDTRONIC PLC

GAAP TO NON-GAAP RECONCILIATIONS(1)

(Unaudited)

Three months ended

(in millions) July 31, 2026 July 25, 2025

Net cash provided by operating activities $ 1,793 $ 1,088

Additions to property, plant, and equipment (503) (504)

Free Cash Flow(2)

$ 1,290 $ 584

See description of non-GAAP financial measures contained in the press release dated September 1, 2026.

(1)The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.

(2)Free cash flow represents operating cash flows less property, plant, and equipment additions.

MEDTRONIC PLC

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Three months ended

(in millions) July 31, 2026 July 25, 2025

Operating Activities:

Net income $ 1,479 $ 1,047

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization 729 748

Provision for credit losses 25 28

Deferred income taxes 127 167

Stock-based compensation 125 86

Other, net (29) 159

Change in operating assets and liabilities, net of acquisitions and divestitures:

Accounts receivable, net 224 288

Inventories (240) (373)

Accounts payable and accrued liabilities (531) (598)

Other operating assets and liabilities (118) (464)

Net cash provided by operating activities 1,793 1,088

Investing Activities:

Acquisitions, net of cash acquired (1,162) —

Additions to property, plant, and equipment (503) (504)

Purchases of investments (2,190) (2,100)

Sales and maturities of investments 2,209 2,010

Other investing activities, net 26 (125)

Net cash used in investing activities (1,619) (719)

Financing Activities:

Change in current debt obligations, net 812 649

Payments on long-term debt — (1,162)

Dividends to shareholders (921) (910)

Issuance of ordinary shares 20 95

Repurchase of ordinary shares (267) (123)

Other financing activities, net 13 70

Net cash used in financing activities (343) (1,381)

Effect of exchange rate changes on cash and cash equivalents (89) 67

Net change in cash and cash equivalents (258) (945)

Cash and cash equivalents at beginning of period 1,949 2,218

Cash and cash equivalents at end of period $ 1,691 $ 1,273

Supplemental Cash Flow Information

Cash paid for:

Income taxes $ 199 $ 402

Interest 83 81

The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.

GRAPHIC — IMAGE 0

GRAPHIC

Filename: image_0a.jpg · Sequence: 7

Binary file (25991 bytes)

Download image_0a.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Sep. 01, 2026

Entity Information [Line Items]

Document Type

8-K

Document Period End Date

Sep. 01, 2026

Entity Incorporation, State or Country Code

Entity File Number

1-36820

Entity Tax Identification Number

98-1183488

Entity Address, Address Line One

Building Two

Entity Address, Address Line Two

Parkmore Business Park West

Entity Address, City or Town

Galway

Entity Address, Country

Country Region

353

City Area Code

Local Phone Number

438-1700

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Ordinary shares, par value $0.0001 per share

Trading Symbol

MDT

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Entity Central Index Key

0001613103

Entity Registrant Name

Medtronic plc

Entity Address, Postal Zip Code

H91 4K49

Amendment Flag

false

1.125% Senior Notes due 2027

Entity Information [Line Items]

Title of 12(b) Security

1.125% Senior Notes due 2027

Trading Symbol

MDT/27

Security Exchange Name

NYSE

0.375% Senior Notes due 2028

Entity Information [Line Items]

Title of 12(b) Security

0.375% Senior Notes due 2028

Trading Symbol

MDT/28

Security Exchange Name

NYSE

3.000% Senior Notes due 2028

Entity Information [Line Items]

Title of 12(b) Security

3.000% Senior Notes due 2028

Trading Symbol

MDT/28A

Security Exchange Name

NYSE

3.650% Senior Notes due 2029

Entity Information [Line Items]

Title of 12(b) Security

3.650% Senior Notes due 2029

Trading Symbol

MDT/29

Security Exchange Name

NYSE

2.950% Senior Notes due 2030

Entity Information [Line Items]

Title of 12(b) Security

2.950% Senior Notes due 2030

Trading Symbol

MDT/30

Security Exchange Name

NYSE

1.625% Senior Notes due 2031

Entity Information [Line Items]

Title of 12(b) Security

1.625% Senior Notes due 2031

Trading Symbol

MDT/31

Security Exchange Name

NYSE

1.000% Senior Notes due 2031

Entity Information [Line Items]

Title of 12(b) Security

1.000% Senior Notes due 2031

Trading Symbol

MDT/31A

Security Exchange Name

NYSE

3.125% Senior Notes due 2031

Entity Information [Line Items]

Title of 12(b) Security

3.125% Senior Notes due 2031

Trading Symbol

MDT/31B

Security Exchange Name

NYSE

0.750% Senior Notes due 2032

Entity Information [Line Items]

Title of 12(b) Security

0.750% Senior Notes due 2032

Trading Symbol

MDT/32

Security Exchange Name

NYSE

3.375% Senior Notes due 2034

Entity Information [Line Items]

Title of 12(b) Security

3.375% Senior Notes due 2034

Trading Symbol

MDT/34

Security Exchange Name

NYSE

3.875% Senior Notes due 2036

Entity Information [Line Items]

Title of 12(b) Security

3.875% Senior Notes due 2036

Trading Symbol

MDT/36

Security Exchange Name

NYSE

2.250% Senior Notes due 2039

Entity Information [Line Items]

Title of 12(b) Security

2.250% Senior Notes due 2039

Trading Symbol

MDT/39A

Security Exchange Name

NYSE

1.500% Senior Notes due 2039

Entity Information [Line Items]

Title of 12(b) Security

1.500% Senior Notes due 2039

Trading Symbol

MDT/39B

Security Exchange Name

NYSE

1.375% Senior Notes due 2040

Entity Information [Line Items]

Title of 12(b) Security

1.375% Senior Notes due 2040

Trading Symbol

MDT/40A

Security Exchange Name

NYSE

4.150% Senior Notes due 2043

Entity Information [Line Items]

Title of 12(b) Security

4.150% Senior Notes due 2043

Trading Symbol

MDT/43A

Security Exchange Name

NYSE

4.200% Senior Notes due 2045

Entity Information [Line Items]

Title of 12(b) Security

4.200% Senior Notes due 2045

Trading Symbol

MDT/45

Security Exchange Name

NYSE

1.750% Senior Notes due 2049

Entity Information [Line Items]

Title of 12(b) Security

1.750% Senior Notes due 2049

Trading Symbol

MDT/49

Security Exchange Name

NYSE

1.625% Senior Notes due 2050

Entity Information [Line Items]

Title of 12(b) Security

1.625% Senior Notes due 2050

Trading Symbol

MDT/50

Security Exchange Name

NYSE

4.150% Senior Notes due 2053

Entity Information [Line Items]

Title of 12(b) Security

4.150% Senior Notes due 2053

Trading Symbol

MDT/53

Security Exchange Name

NYSE

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Region code of country

+ References

No definition available.

+ Details

Name:

dei_CountryRegion

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_EntityInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A1.125SeniorNotesDue2027Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A0.375SeniorNotesDue2028Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A3.000SeniorNotesDue2028Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A3.650SeniorNotesDue2029Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A2.950SeniorNotesDue2030Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A1.625SeniorNotesDue2031Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A1.000SeniorNotesDue2031Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A3.125SeniorNotesDue2031Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A0.750SeniorNotesDue2032Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A3.375SeniorNotesDue2034Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A3.875SeniorNotesDue2036Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A2.250SeniorNotesDue2039Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A1.500SeniorNotesDue2039Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A1.375SeniorNotesDue2040Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A4.150SeniorNotesDue2043Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A4.200SeniorNotesDue2045Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A1.750SeniorNotesDue2049Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A1.625SeniorNotesDue2050Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_DebtInstrumentAxis=mdt_A4.150SeniorNotesDue2053Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type: